News & Analysis as of

Genentech Fresenius

Goodwin

PTAB Institutes Another IPR on a Tocilizumab Patent Challenged by Fresenius

Goodwin on

On March 3, 2022, the PTAB instituted another inter partes review of U.S. Patent Nos. 8,580,264 (“the ’264 patent”), owned by Chugai and Roche. Fresenius filed a petition for inter partes review of the ‘264 patent,...more

Goodwin

Year in Review: Top 5 Biosimilars Deals of 2017

Goodwin on

Here are our picks for the top-5 biggest deals in the world of biosimilars in 2017...more

2 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide